<DOC>
	<DOC>NCT01043263</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of EN3324 (axomadol) in subjects with moderate to severe chronic low back pain</brief_summary>
	<brief_title>Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain</brief_title>
	<detailed_description>A phase IIB, randomized, double-blind, two-arm, multi-center, placebo-controlled, study to assess the efficacy and safety of EN3324 (axomadol) in subjects with moderate to severe chronic low back pain</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>18 years of age or older Are females who are participating abstinence or using a medically acceptable form of contraception or have been postmenopausal, biologically sterile, or surgically sterile for more than 1 year. Have been on an unchanged regimen of analgesic medication for chronic low back pain on a daily basis for at least 3 months prior to screening; subjects taking opioids must not exceed total daily doses of 90mg oral morphine equivalent Have a history of moderate to severe CLBP Have evidence of or a history of alcohol and/or drug abuse Have pain secondary to a confirmed or suspected neoplasm Intend to alter their physical therapy regimen during the study. Subjects who begin or end physical therapy (either home exercises or formal therapy sessions) 2 weeks prior to screening or during the study period will be excluded from the study Have a history or physical examination finding, which may confound painrelated data (e.g., fibromyalgia, radiculopathy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>